NASDAQ:AMPH - Amphastar Pharmaceuticals Stock Price, Forecast & News

Amphastar Pharmaceuticals trades on the NASDAQ under the ticker symbol "AMPH."

Amphastar Pharmaceuticals Inc (NASDAQ:AMPH) announced its quarterly earnings results on Thursday, November, 7th. The company reported $0.10 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.08 by $0.02. The firm earned $80.14 million during the quarter, compared to the consensus estimate of $78.53 million. Amphastar Pharmaceuticals had a return on equity of 5.07% and a net margin of 15.77%. The firm's quarterly revenue was up 6.1% compared to the same quarter last year. During the same period in the prior year, the firm earned $0.12 EPS. View Amphastar Pharmaceuticals' Earnings History.

Amphastar Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March 10th 2020. View Earnings Estimates for Amphastar Pharmaceuticals.

3 equities research analysts have issued 12-month target prices for Amphastar Pharmaceuticals' shares. Their forecasts range from $22.20 to $29.00. On average, they expect Amphastar Pharmaceuticals' share price to reach $24.73 in the next year. This suggests a possible upside of 23.3% from the stock's current price. View Analyst Price Targets for Amphastar Pharmaceuticals.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amphastar Pharmaceuticals in the last year. There are currently 2 hold ratings and 1 buy rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Amphastar Pharmaceuticals.

News coverage about AMPH stock has been trending somewhat positive this week, InfoTrie Sentiment reports. The research firm identifies negative and positive media coverage by analyzing more than six thousand news and blog sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Amphastar Pharmaceuticals earned a daily sentiment score of 1.8 on InfoTrie's scale. They also gave media headlines about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an effect on the company's share price in the immediate future. View News Stories for Amphastar Pharmaceuticals.

Amphastar Pharmaceuticals saw a drop in short interest during the month of December. As of December 31st, there was short interest totalling 2,700,000 shares, a drop of 5.6% from the December 15th total of 2,860,000 shares. Based on an average daily trading volume, of 223,000 shares, the days-to-cover ratio is presently 12.1 days. Approximately 7.6% of the company's shares are short sold. View Amphastar Pharmaceuticals' Current Options Chain.

Some companies that are related to Amphastar Pharmaceuticals include Mirati Therapeutics (MRTX), GW Pharmaceuticals PLC- (GWPH), Ultragenyx Pharmaceutical (RARE), Deciphera Pharmaceuticals (DCPH), PTC Therapeutics (PTCT), HUTCHISON CHINA/S (HCM), Taro Pharmaceutical Industries (TARO), Intercept Pharmaceuticals (ICPT), Myokardia (MYOK), Apellis Pharmaceuticals (APLS), Agios Pharmaceuticals (AGIO), Axsome Therapeutics (AXSM), Zai Lab (ZLAB), Biohaven Pharmaceutical (BHVN) and Emergent Biosolutions (EBS).

Based on aggregate information from My MarketBeat watchlists, some companies that other Amphastar Pharmaceuticals investors own include Cara Therapeutics (CARA), Gilead Sciences (GILD), Amicus Therapeutics (FOLD), Exelixis (EXEL), CNX Resources (CNX), AbbVie (ABBV), Advanced Micro Devices (AMD), Cellectis (CLLS), Clovis Oncology (CLVS) and Neurocrine Biosciences (NBIX).

Amphastar Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional investors include Nisa Investment Advisors LLC (0.06%), State of Alaska Department of Revenue (0.06%) and Louisiana State Employees Retirement System (0.02%). Company insiders that own Amphastar Pharmaceuticals stock include Floyd F Petersen, Howard Lee, Jack Y Zhang, Jason B Shandell, Michael A Zasloff, Physics & Chemistry La Applied, Richard K Prins, Richard Koo, Rong Zhou, William J Peters and Yakob Liawatidewi. View Institutional Ownership Trends for Amphastar Pharmaceuticals.

AMPH stock was sold by a variety of institutional investors in the last quarter, including Louisiana State Employees Retirement System and State of Alaska Department of Revenue. Company insiders that have sold Amphastar Pharmaceuticals company stock in the last year include Floyd F Petersen, Jack Y Zhang, Jason B Shandell, Richard K Prins, Rong Zhou, William J Peters and Yakob Liawatidewi. View Insider Buying and Selling for Amphastar Pharmaceuticals.

AMPH stock was purchased by a variety of institutional investors in the last quarter, including Nisa Investment Advisors LLC. View Insider Buying and Selling for Amphastar Pharmaceuticals.

Shares of AMPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of AMPH stock can currently be purchased for approximately $20.06.

Amphastar Pharmaceuticals has a market capitalization of $941.62 million and generates $294.67 million in revenue each year. The company earns $-5,740,000.00 in net income (profit) each year or $0.21 on an earnings per share basis. Amphastar Pharmaceuticals employs 2,078 workers across the globe.View Additional Information About Amphastar Pharmaceuticals.

The official website for Amphastar Pharmaceuticals is http://www.amphastar.com/.

Amphastar Pharmaceuticals' mailing address is 11570 SIXTH STREET, RANCHO CUCAMONGA CA, 91730. The company can be reached via phone at 909-980-9484 or via email at [email protected]